Abstract
Newborn hyperbilirubinemia during the first two weeks of life is one of most common problems requiring management decisions by a pediatrician. However, high bilirubin levels in the circulation have been associated with neurologic injury under a variety of conditions encountered in the newborn infant, such as hemolysis. The risk for developing dangerous hyperbilirubinemia is multifactorial and is determined by a complex set of factors related to a newborn infant’s genetic capacities as well as intra- and extrauterine exposures. To this end, a precision health approach based on the integration of prenatal genetic and postnatal diagnostic measures might improve the management of neonatal hyperbilirubinemia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med. 2001;344:581–90.
Kemper AR, Newman TB, Slaughter JL, Maisels MJ, Watchko JF, Downs SM, et al. Clinical Practice Guideline Revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022;150:e2022058859.
Hansen TWR, Wong RJ, Stevenson DK. Molecular physiology and pathophysiology of bilirubin handling by the blood, liver, intestine, and brain in the newborn. Physiol Rev. 2020;100:1291–346.
Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA. 1968;61:748–55.
Wong RJ, Bhutani VK, Stevenson DK. The importance of hemolysis and Its clinical detection in neonates with hyperbilirubinemia. Curr Pediatr Rev. 2017;13:193–8.
Lamola AA, Bhutani VK, Du L, Castillo Cuadrado M, Chen L, Shen Z, et al. Neonatal bilirubin binding capacity discerns risk of neurological dysfunction. Pediatr Res. 2015;77:334–9.
Bhutani VK, Wong RJ. Bilirubin neurotoxicity in preterm infants: risk and prevention. J Clin Neonatol. 2013;2:61–9.
Bhutani VK, Wong R. Bilirubin-induced neurologic dysfunction (BIND). Semin Fetal Neonatal Med. 2015;20:1.
Tidmarsh GF, Wong RJ, Stevenson DK. End-tidal carbon monoxide and hemolysis. J Perinatol. 2014;34:577–81.
Bhutani VK, Srinivas S, Castillo Cuadrado ME, Aby JL, Wong RJ, Stevenson DK. Identification of neonatal haemolysis: an approach to predischarge management of neonatal hyperbilirubinemia. Acta Paediatr. 2016;105:e189–e94.
Christensen RD, Bahr TM, Wong RJ, Vreman HJ, Bhutani VK, Stevenson DK. A “Gold Standard” test for diagnosing and quantifying hemolysis in neonates and infants. J Perinatol. 2023;43:1541–7.
Stevenson DK, Fanaroff AA, Maisels MJ, Young BW, Wong RJ, Vreman HJ, et al. Prediction of hyperbilirubinemia in near-term and term infants. Pediatrics. 2001;108:31–9.
Bhutani VK, Maisels MJ, Schutzman DL, Castillo Cuadrado ME, Aby JL, Bogen DL, et al. Identification of risk for neonatal haemolysis. Acta Paediatr. 2018;107:1350–6.
Valaes T. Problems with prediction of neonatal hyperbilirubinemia. Pediatrics. 2001;108:175–7.
Kaplan M, Hammerman C, Maisels MJ. Bilirubin genetics for the nongeneticist: hereditary defects of neonatal bilirubin conjugation. Pediatrics. 2003;111:886–93.
Watchko JF, Lin Z. Exploring the genetic architecture of neonatal hyperbilirubinemia. Semin Fetal Neonatal Med. 2010;15:169–75.
Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharm Toxicol. 1997;37:517–54.
Kaplan M, Wong RJ, Stevenson DK. Hemolysis and glucose-6-phosphate dehydrogenase deficiency-related neonatal hyperbilirubinemia. Neonatology. 2018;114:223–5.
Morris BH, Oh W, Tyson JE, Stevenson DK, Phelps DL, O’Shea TM, et al. Aggressive vs. conservative phototherapy for infants with extremely low birth weight. N. Engl J Med. 2008;359:1885–96.
Arnold C, Tyson JE, Pedroza C, Carlo WA, Stevenson DK, Wong RJ, et al. Cycled phototherapy dose-finding study for extremely low-birth-weight infants: a randomized clinical trial. JAMA Pediatr. 2020;174:649–56.
Maines MD. Zinc•protoporphyrin is a selective inhibitor of heme oxygenase activity in the neonatal rat. Biochim Biophys Acta. 1981;673:339–50.
Stevenson DK, Rodgers PA, Vreman HJ. The use of metalloporphyrins for the chemoprevention of neonatal jaundice. Am J Dis Child. 1989;143:353–6.
Vreman HJ, Wong RJ, Stevenson DK. Alternative metalloporphyrins for the treatment of neonatal jaundice. J Perinatol. 2001;21:S108–13.
Schulz S, Wong RJ, Vreman HJ, Stevenson DK. Metalloporphyrins – an update. Front Pharm. 2012;3:68.
Kappas A, Drummond GS, Manola T, Petmezaki S, Valaes T. Sn-protoporphyrin use in the management of hyperbilirubinemia in term newborns with direct Coombs-positive ABO incompatibility. Pediatrics. 1988;81:485–97.
Valaes T, Drummond GS, Kappas A. Control of hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient newborns using an inhibitor of bilirubin production, Sn-mesoporphyrin. Pediatrics. 1998;101:E1.
Valaes T, Petmezaki S, Henschke C, Drummond GS, Kappas A. Control of jaundice in preterm newborns by an inhibitor of bilirubin production: studies with tin-mesoporphyrin. Pediatrics. 1994;93:1–11.
Martinez JC, Garcia HO, Otheguy LE, Drummond GS, Kappas A. Control of severe hyperbilirubinemia in full-term newborns with the inhibitor of bilirubin production Sn-mesoporphyrin. Pediatrics. 1999;103:1–5.
Bhutani VK, Poland R, Meloy LD, Hegyi T, Fanaroff AA, Maisels MJ. Clinical trial of tin mesoporphyrin to prevent neonatal hyperbilirubinemia. J Perinatol. 2016;36:533–9.
Rosenfeld WN, Hudak ML, Ruiz N, Gautam S, Jasmine Study Group. Stannsoporfin with phototherapy to treat hyperbilirubinemia in newborn hemolytic disease. J Perinatol. 2022;42:110–5.
Kappas A. A method for interdicting the development of severe jaundice in newborns by inhibiting the production of bilirubin. Pediatrics. 2004;113:119–23.
Alexander D. A method for interdicting the development of severe jaundice in newborns by inhibiting the production of bilirubin. Pediatrics. 2004;113:135.
Fujioka K, Kalish F, Wong RJ, Stevenson DK. Inhibition of heme oxygenase activity using a microparticle formulation of zinc protoporphyrin in an acute hemolytic newborn mouse model. Pediatr Res. 2016;79:251–7.
Wong RJ, Schulz S, Espadas C, Vreman HJ, Rajadas J, Stevenson DK. Effects of light on metalloporphyrin-treated newborn mice. Acta Paediatr. 2014;103:474–9.
Poudel P, Adhikari S. Efficacy and safety concerns with Sn-mesoporphyrin as an adjunct therapy in neonatal hyperbilirubinemia: a literature review. Int J Pediatr. 2022;2022:2549161.
Rodgers PA, Seidman DS, Wei PL, Dennery PA, Stevenson DK. Duration of action and tissue distribution of zinc protoporphyrin in neonatal rats. Pediatr Res. 1996;39:1041–9.
Vreman HJ, Rodgers PA, Stevenson DK. Zinc protoporphyrin administration for suppression of increased bilirubin production by iatrogenic hemolysis in rhesus neonates. J Pediatr. 1990;117:292–7.
Rodgers PA, Vreman HJ, Stevenson DK. Heme catabolism in rhesus neonates inhibited by zinc protoporphyrin. Dev Pharm Ther. 1990;14:216–22.
Labbe RF, Vreman HJ, Stevenson DK. Zinc protoporphyrin: a metabolite with a mission. Clin Chem. 1999;45:2060–72.
Wang J, Guo G, Li A, Cai WQ, Wang X. Challenges of phototherapy for neonatal hyperbilirubinemia (Review). Exp Ther Med. 2021;21:231.
Terrin G, Boscarino G, Di Chiara M, Iacobelli S, Faccioli F, Greco C, et al. Nutritional intake influences zinc levels in preterm newborns: an observational study. Nutrients. 2020;12:529.
Funding
No funding was secured for this study.
Author information
Authors and Affiliations
Contributions
DKS drafted the initial manuscript, revised the manuscript, and approved the final version. GSW and RJW critically reviewed the manuscript, revised the manuscript, and approved the final version as submitted. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Competing interests
DKS has no conflicts of interest to disclose. GSW and RJW are co-founders of Metallic Bio.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Stevenson, D.K., Wells, G.S. & Wong, R.J. Is it time for a precision health approach to the management of newborn hyperbilirubinemia?. J Perinatol (2024). https://doi.org/10.1038/s41372-024-01941-3
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41372-024-01941-3